Department of Neuroscience, Blizard Institute, Queen Mary University of London
BTKi Treatment Paradigm
Neurology experts discuss where BTKi’s fit in the multiple sclerosis treatment continuum.
BTKi Treatment: Clinical Measures
Experts provide insights about what clinical measures they look for when treating patients with BTKis for multiple sclerosis.
BTKi Effect on Chronic Active Lesions
Neurology experts discuss the potential effects of BTKi on chronic active lesions during multiple sclerosis therapies.
BTKi Mechanism of Action
Neurology experts discuss the mechanism of action of BTKi’s for the treatment of multiple sclerosis.
BTKi Safety Concerns
Experts lead a discussion about potential safety concerns of BTKi’s when treating patients with multiple sclerosis.
Medical Gaslighting: Multiple Sclerosis’ Dirty Little Secret?
The effect of gaslighting on patients can result in serious harms, and although it is potentially common in the MS care continuum, whether it is deliberate or an institutional problem, it must be called out by providers.
Phase II Clinical Trial: Tolebrutinib
Jiwon Oh, MD, PhD, FRCPC, provides an overview of phase II results of tolebrutinib for the treatment of multiple sclerosis.
Phase II Clinical Trial: Fenebrutinib
Amit Bar-Or, MD, FRCPC, summarizes fenebrutinib phase II results for the treatment of multiple sclerosis.
Phase II Clinical Trial: Evobrutinib
Patrick Vermersch, MD, PhD, summarizes phase II clinical trial of evobrutinib for the treatment of multiple sclerosis.
BTK Inhibitor Clinical Development
Patrick Vermersch, MD, PhD, and Krzysztof Selmaj, MD, PhD, provide an overview of the BTKi that are currently under investigation for MS, and Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, discusses what in vivo and in vitro preclinical work in models of MS have shown.
BTK Inhibitor Overview
Amit Bar-Or, MD, FRCPC, provides an overview of the history of BTKi’s as well as what makes this class of drug a promising target for relapsing and remitting forms of MS.
Rethinking MS as a Smoldering Disease and the Role of the Epstein Barr Virus: Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath
At CMSC 2023, the professor of neurology at Barts and The London School of Medicine and Dentistry discussed the emerging paradigm shift in understanding multiple sclerosis (MS) as a smoldering disease and the potential role of Epstein Barr Virus in causing MS. [WATCH TIME: 6 minutes]
Future of Relapsing MS Management
Key opinion leaders in multiple sclerosis (MS) discuss the future of relapsing MS management and unmet needs.
Biomarkers for Monitoring Treatment Response in Relapsing MS
Expert neurologists discuss current and future biomarkers relevant to relapsing multiple sclerosis including cerebrospinal fluid neurofilament.
Shared Decision Making and Lifestyle Issues in Relapsing MS
A panel of experts emphasize the importance of shared decision making in relapsing multiple sclerosis and discuss lifestyle choices that impact the disease.
Sequencing Therapies in Relapsing MS
Experts in multiple sclerosis (MS) discuss key factors involved in the sequencing of therapies for relapsing MS.
Monitoring Outcomes in Relapsing MS
Lauren Gluck, MD discusses considerations for monitoring response to treatment in relapsing multiple sclerosis.
Overview of Teriflunomide for Relapsing MS
Lauren Gluck, MD, and Ravi Dukkipati, MD, provide an overview of teriflunomide for relapsing multiple sclerosis including its safety and tolerability profile.
Considerations for the Use of Fumarates in Relapsing MS
Experts in the field of multiple sclerosis provide insight into the fumarates as a viable oral option for relapsing MS.
Anti-CD20 Agents for Relapsing MS
A panel of experts discuss the use of anti-CD20 monoclonal antibodies in relapsing multiple sclerosis including summaries of the phase III ORATORIO and ASCLEPIOS trials, for ocrelizumab and ofatumumab, respectively.
Role of S1P Receptor Modulators in Relapsing MS
Expert neurologists discuss the role of sphingosine-1-phosphate (S1P) receptor modulators in relapsing multiple sclerosis including vaccine considerations and pediatric use.
Cladribine in Relapsing MS
Key opinion leaders provide insight into the use cladribine for relapsing multiple sclerosis including durability and safety profile.
Cladribine: History and Mechanism of Action in MS
Gavin Giovannoni, MD provides an overview of the development and pharmacodynamics of cladribine in multiple sclerosis.
Platform Agents for MS: Interferons and Glatiramer
Fred D. Lublin, MD, Ravi Dukkipati, MD, and Lauren Gluck, MD, discuss interferons and glatiramer as platform therapies in multiple sclerosis.
Treatment Strategy for Relapsing MS
Experts in multiple sclerosis (MS) provide an overview of treatment strategies and selection in relapsing MS.
The Diagnosis of Multiple Sclerosis
Fred D. Lublin, MD discusses the diagnosis of multiple sclerosis and the 2017 revisions of the McDonald criteria.
2 Commerce Drive Cranbury, NJ 08512